Title | Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review. |
Publication Type | Journal Article |
Year of Publication | 2023 |
Authors | Askari E, Moghadam SZarehparva, Wild D, Delpassand E, Baldari S, Nilica B, Hartrampf PE, Kong G, Grana CMaria, Walter MAlexander, Capoccetti F, Kasi PMurtaza, Strosberg J |
Journal | J Nucl Med Technol |
Volume | 51 |
Issue | 1 |
Pagination | 22-25 |
Date Published | 2023 Mar |
ISSN | 1535-5675 |
Keywords | Carcinoma, Merkel Cell, Humans, Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Prospective Studies, Radioisotopes, Receptors, Somatostatin, Retrospective Studies, Skin Neoplasms |
Abstract | Merkel cell carcinoma is a rare, aggressive skin malignancy, also known as neuroendocrine carcinoma of the skin, with high rates of recurrence and distant metastasis. In refractory metastatic Merkel cell carcinoma (mMCC), besides immunotherapy, chemotherapy, and radiation, peptide receptor radionuclide therapy (PRRT) may be a viable option since this type of tumor can express somatostatin receptors. We performed a comprehensive review of the literature to evaluate the efficacy of PRRT in mMCC patients. Thirty-seven patients with mMCC received PRRT (1-5 cycles) with Lu- or Y-labeled somatostatin analogs (cumulative activity, 1.5-30 GBq). Radiographic response was available for 19 of 28 patients who received PRRT alone. Six (31.6%) of 19 patients showed objective responses, from partial to complete, and no severe adverse events were reported. Our analysis supports the use of PRRT in mMCC with sufficient somatostatin receptor uptake, although the quality of the available evidence is low. Prospective clinical trials are already in development and have started accruing in some parts of the world. |
DOI | 10.2967/jnmt.122.264904 |
Alternate Journal | J Nucl Med Technol |
PubMed ID | 36195446 |